INBS — INTELLIGENT BIO SOLUTIONS INC.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1725430 ·
Last close
$2.65
Market Cap
$6.34M
52W High
$5.20
52W Low
$2.27
ADV30
158,824
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | 535,381 | — | -2,862,712 | — | 6,862,204 | — |
| Dec 2025 | 896,774 | 459,739 | -2,608,591 | -2,677,590 | 17,653,042 | 740,371 | 6,763,231 |
| Sep 2025 | 1,111,797 | 518,291 | -2,737,813 | -2,983,006 | 10,038,309 | 1,660,105 | 6,611,380 |
| Jun 2025 | 843,884 | 335,577 | -2,881,554 | -3,090,104 | 8,249,786 | 1,019,909 | 5,435,962 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,379,685
Investing CF
$-321,377
Financing CF
$8,156,427
CapEx
$-361,535
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-15.68
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-68,193,661
Inventory
$590,246
Receivables
$10,363,934
ST Investments
—
EBIT TTM
$-11,249,722
Pretax Income TTM
$-11,334,895
Interest Exp TTM
$85,173
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,913,257
EBITDA
$-10,233,371
Free Cash Flow
$-6,492,149
Enterprise Value
$923,015
Total Cash
$6,862,204
Total Debt
$1,848,424
Shares Out
2,391,846
Trailing EPS
$-11.62
Book Value
$4.48
ROE
-170.2%
ROA
-57.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 3,052,532 | -10,424,545 | -10,568,733 | 8,249,786 | 5,435,962 | — | -9,677,313 |
| Jun 2024 | 3,111,781 | -10,283,174 | -10,156,759 | 13,778,863 | 5,595,672 | — | -9,571,569 |
| Jun 2023 | 1,256,872 | -8,436,563 | -10,631,720 | 10,354,612 | 6,667,614 | — | -7,377,378 |
| Jun 2022 | 0 | -8,336,876 | -8,306,051 | 12,352,173 | 5,806,402 | — | -3,358,034 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.35
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MHUAF | Meihua International Medical Technologies Co., Ltd. | $6.33M | $7.40 | — |
| RBOT | Vicarious Surgical Inc. | $6.21M | $0.96 | — |
| HSCS | HeartSciences Inc. | $6.15M | $1.93 | — |
| STME | Stimcell Energetics Inc. | $6.13M | $0.29 | — |
| NDRA | ENDRA Life Sciences Inc. | $6.60M | $5.20 | — |
News headlines (Yahoo Finance, 1h cache)
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
2026-05-13 12:30 · Yahoo
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results
2026-04-20 13:15 · Yahoo
Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified
2026-04-17 12:30 · Yahoo
Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
2026-04-02 12:30 · Yahoo
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
2026-03-26 12:30 · Yahoo
Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry
2026-02-25 13:45 · Yahoo
Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
2026-02-24 13:45 · Yahoo
Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year
2026-02-12 13:30 · Yahoo
Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
2026-02-05 13:30 · Yahoo
Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market
2026-01-28 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.